(Q37194359)

18 August 2017

Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop (English)

1 reference

18 August 2017

0 references

5

Zoe Moodie

1 reference

18 August 2017

2

Ann Duerr

1 reference

18 August 2017

8

Steve Self

1 reference

18 August 2017

Dean Follmann

1

1 reference

18 August 2017

Stephen Tabet

3

1 reference

18 August 2017

Peter Gilbert

4

1 reference

18 August 2017

Patricia Fast

6

1 reference

18 August 2017

Massimo Cardinali

7

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

Journal of Acquired Immune Deficiency Syndromes

18 August 2017

1 reference

18 August 2017

44

1 reference

18 August 2017

1

1 reference

18 August 2017

49-60

1 reference

Design and analysis of stepped wedge cluster randomized trials

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2682948

Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2682948

Once-daily valacyclovir to reduce the risk of transmission of genital herpes

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2682948

Sensitivity Analysis for the Assessment of Causal Vaccine Effects on Viral Load in HIV Vaccine Trials

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2682948

Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2682948

HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2682948

Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2682948

Design and interpretation of vaccine field studies.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2682948

The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2682948

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2682948

Direct and indirect effects in vaccine efficacy and effectiveness

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2682948

Statistical Issues in the Design of HIV Vaccine Trials

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2682948

Trial objectives and end points for measuring the efficacy of HIV vaccines

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2682948

Intermediate-size trials for the evaluation of HIV vaccine candidates: a workshop summary

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2682948

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2682948

What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2682948

Reduction in burden of illness: a new efficacy measure for prevention trials

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2682948

Study designs for dependent happenings

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2682948

Initial plasma HIV-1 RNA levels and progression to AIDS in women and men

20 October 2018

1 reference

12 December 2020

Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4+ Cell Strata

1 reference

12 December 2020

On the analysis of viral load endpoints in HIV vaccine trials

1 reference

12 December 2020

The Gambia Hepatitis Intervention Study. The Gambia Hepatitis Study Group

1 reference

12 December 2020

Evaluating new vaccines for developing countries. Efficacy or effectiveness?

1 reference

12 December 2020

Measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV-1 vaccines

1 reference

12 December 2020

10.1097/01.QAI.0000247227.22504.CE

Identifiers

DOI

1 reference

18 August 2017

1 reference

18 August 2017

PubMed publication ID

17075387

1 reference